Jazz Pharmaceuticals (NASDAQ:JAZZ) Earns "Buy" Rating from Needham & Company LLC

Key Points

• Needham & Company LLC has reaffirmed a "Buy" rating for Jazz Pharmaceuticals (NASDAQ:JAZZ) with a target price of $202.00, indicating a potential upside of 62.34% from its previous close.
• Jazz Pharmaceuticals reported a quarterly earnings miss with a loss of ($8.25) earnings per share, below analysts' expectations, but achieved revenue of $1.05 billion for the quarter.
• The stock has received mixed ratings from various analysts, with a consensus rating of "Moderate Buy" and a consensus target price of $181.43.

Needham & Company LLC reaffirmed their buy rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ - Free Report) in a research note released on Thursday,Benzinga reports. Needham & Company LLC currently has a $202.00 price objective on the specialty pharmaceutical company's stock.

Several other research analysts also recently commented on JAZZ. Royal Bank Of Canada cut their target price on Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. Piper Sandler restated an "overweight" rating and issued a $147.00 target price (down from $176.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 7th. Morgan Stanley decreased their target price on Jazz Pharmaceuticals from $165.00 to $162.00 and set an "overweight" rating on the stock in a research note on Wednesday, August 6th. Zacks Research upgraded Jazz Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Friday, August 15th. Finally, Deutsche Bank Aktiengesellschaft began coverage on Jazz Pharmaceuticals in a research note on Tuesday, July 15th. They issued a "buy" rating and a $152.00 target price on the stock. Fourteen research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat, Jazz Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $178.67.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ stock traded up $1.62 during trading hours on Thursday, hitting $127.75. 675,563 shares of the company were exchanged, compared to its average volume of 900,719. The firm has a fifty day simple moving average of $114.48 and a 200 day simple moving average of $117.11. The company has a current ratio of 1.62, a quick ratio of 1.37 and a debt-to-equity ratio of 1.17. Jazz Pharmaceuticals has a 52-week low of $95.49 and a 52-week high of $148.06. The stock has a market capitalization of $7.75 billion, a price-to-earnings ratio of -18.98, a P/E/G ratio of 8.05 and a beta of 0.34.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.61) by ($2.64). The company had revenue of $1.05 billion for the quarter, compared to analysts' expectations of $1.05 billion. Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The company's revenue for the quarter was up 2.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $5.30 EPS. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. Research analysts predict that Jazz Pharmaceuticals will post 16.96 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of the business's stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $107.63, for a total value of $107,630.00. Following the completion of the sale, the chief executive officer directly owned 436,973 shares of the company's stock, valued at $47,031,403.99. The trade was a 0.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 4.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vestal Point Capital LP purchased a new position in shares of Jazz Pharmaceuticals in the second quarter valued at about $127,344,000. Nuveen LLC purchased a new position in shares of Jazz Pharmaceuticals in the first quarter valued at about $62,362,000. Fuller & Thaler Asset Management Inc. increased its position in shares of Jazz Pharmaceuticals by 41.7% in the first quarter. Fuller & Thaler Asset Management Inc. now owns 1,331,011 shares of the specialty pharmaceutical company's stock valued at $165,245,000 after acquiring an additional 391,660 shares during the period. Perpetual Ltd increased its position in shares of Jazz Pharmaceuticals by 60.2% during the first quarter. Perpetual Ltd now owns 952,172 shares of the specialty pharmaceutical company's stock valued at $118,212,000 after buying an additional 357,784 shares during the period. Finally, Ameriprise Financial Inc. increased its position in shares of Jazz Pharmaceuticals by 20.9% during the fourth quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company's stock valued at $225,076,000 after buying an additional 315,608 shares during the period. 89.14% of the stock is currently owned by institutional investors.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.